Mucomyst for Hepatitis C

• Status: Suspended
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will examine the effects of treatment with N-acetylcysteine ( Mucomyst ) 1 gm twice a day for 30 dyas in 15 patients with hepatitis C. The primary outcome of interest wil be the changes in oxidant stress as measured by different oxidant stress markers level in sera. Secondary outcomes of interest will be changes in viral load of hep C and changes in liver function

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Collaborator: West Virginia University
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Patient with known hepatitis C

Exclusion Criteria:

• Patient on another therapy for Hep C

• Patient on dialysis

• Patient who are allergic to Mucomyst